It’s hard to feel much worse than when tired and jet-lagged from the 16-hour flight to Thailand. Perhaps only after then ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Morning light resets the rhythm. By evening, levels of a hormone called melatonin begin to surge, triggering drowsiness. Too ...

Becton, Dickinson and Company ( BDX) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDT Good morning. Thanks very much for joining us. Very pleased today to have with us Tom ...

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

Leerink Global Healthcare Conference 2026 March 10, 2026 2:20 PM EDTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04. A real-world cohort of patients with ...

CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...

The survey conducted by AAHA and Gallant found 95% of industry professionals think stem cell therapy will become a new spectrum of care standard treatment option within 10 years. The American Animal ...

ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.